Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. METHODS: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. RESULTS: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [189]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“Any type of irAE occurs in 80-90% of patients, with higher grade events (as categorized by the Common Terminology Criteria for Adverse Events) occurring in 15-20% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 60% of patients treated with combination of ipilimumab and nivolumab.9”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 2×
“AJCC denotes American Joint Committee on Cancer 2009 classification, 7th edition.(14) 0.”
BackgroundSelf-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Self-citation
Cited by
Items 201–300 of 1,000
Patel, J. J., Levy, D. A., Nguyen, S. A., Knochelmann, H. M., & Day, T. A. (2019) · Head & Neck · doi:10.1002/hed.26036 · Cited by 88
“Seiwert (2016) Phase Ib 2b 60 49 (82) 63 (20-83) Pembrolizumab PD1 USA and Israel”
BackgroundInfluentialUnlocking the therapeutic potential of primary tumor-draining lymph nodes
Rotman, J., Koster, B. D., Jordanova, E. S., Heeren, A. M., & de Gruijl, T. D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02330-y · Cited by 83
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 86
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 96
Melanoma of unknown primary: New perspectives for an old story
Boussios, S., Rassy, E., Samartzis, E., Moschetta, M., Sheriff, M., Pérez-Fidalgo, J. A., & Pavlidis, N. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103208 · Cited by 77
The new era of adjuvant therapies for melanoma
Eggermont, A. M. M., Robert, C., & Ribas, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0048-5 · Cited by 82
Self-citationThe concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
Zaremba, A., Eggermont, A. M. M., Robert, C., Dummer, R., Ugurel, S., Livingstone, E., Ascierto, P. A., Long, G. V., Schadendorf, D., & Zimmer, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.002 · Cited by 92
Self-citationJansen, Y. J. L., Krüse, V., Corthals, J., Schats, K., van Dam, P., Seremet, T., Heirman, C., Brochez, L., Kockx, M. M., Thielemans, K., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02618-4 · Cited by 80
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 81
“CheckMate 238 trial, or adjuvant pembrolizumab based on the results of the recent phase III clinical trial (46% of panelists) [31, 32, 37].”
BackgroundMethodLuke, J. J., Ascierto, P. A., Carlino, M. S., Gershenwald, J. E., Grob, J., Hauschild, A., Kirkwood, J. M., Long, G. V., Mohr, P., Robert, C., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0666 · Cited by 78
Self-citationChorti, E., Kanaki, T., Zimmer, L., Hadaschik, E. N., Ugurel, S., Gratsias, E., Roesch, A., Bonella, F., Wessendorf, T., Wälscher, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.024 · Cited by 84
Self-citationInfluenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Awadalla, M., Golden, D. L. A., Mahmood, S., Alvi, R. M., Mercaldo, N. D., Hassan, M. Z. O., Banerji, D., Rokicki, A., Mulligan, C. P., Murphy, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0535-y · Cited by 79
It Is Time to Talk About Fertility and Immunotherapy
Duma, N., & Lambertini, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0837 · Cited by 77
“In February 2019, based on the results of the KEYNOTE-054 trial [2], pembrolizumab received its first approval in the adjuvant setting in the U.”
BackgroundThe Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 89
“, 2021) [41,42] Adjuvant pembrolizumab vs.”
BackgroundInfluentialTargeted Therapy and Immunotherapy in Melanoma
Lazaroff, J. M., & Bolotin, D. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.007 · Cited by 83
Wu, L., Tsang, V., Menzies, A. M., Sasson, S. C., Carlino, M. S., Brown, D. A., Clifton-Bligh, R., & Gunton, J. E. (2023) · Diabetes Care · doi:10.2337/dc22-2202 · Cited by 68
Self-citationGoodman, R. S., Lawless, A. R., Woodford, R. G., Fa’ak, F., Tipirneni, A., Patrinely, J. R., Yeoh, H., Rapisuwon, S., Haydon, A. M., Osman, I., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.27145 · Cited by 85
Self-citationdu Rusquec, P., de Calbiac, O., Robert, M., Campone, M., & Frenel, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s151023 · Cited by 83
“Recently, the FDA has accepted a supplemental biologics license application (sBLA) for the use of pembrolizumab as an adjuvant treatment for patients with high-risk resected stage III melanoma, based on the KEYNOTE-054 trial.(36) Hazard ratio for recurrence or death was 0.”
Wong, P. F., Wei, W., Gupta, S., Smithy, J. W., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0675-0 · Cited by 79
da Silva, I. P., Wang, K. Y. X., Wilmott, J. S., Holst, J., Carlino, M. S., Park, J., Quek, C. Y. J., Wongchenko, M. J., Yan, Y., Mann, G. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1680 · Cited by 76
Self-citationSun, Y., Mo, L., Hu, X., Yu, D., Xie, S., Li, J., Zhao, Z., Fang, X., Ye, M., Qiu, L., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c09093 · Cited by 77
Diagnosis and Management of Acral Lentiginous Melanoma
Nakamura, Y., & Fujisawa, Y. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0560-y · Cited by 80
Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00081-4 · Cited by 81
Self-citationVulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment
Wohlmuth, C., & Wieser, I. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00614-7 · Cited by 75
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 80
Cai, J., Zhang, P., Cai, Y., Zhu, G., Chen, S., Song, L., Du, J.-X., Wang, B., Dai, W., Zhou, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202413095 · Cited by 103
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 79
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 81
Pavlick, A., Blazquez, A. B., Meseck, M., Lattanzi, M., Ott, P. A., Marron, T. U., Holman, R. M., Mandeli, J., Salazar, A. M., McClain, C. B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0545 · Cited by 75
“org Cancer Immunol Res; 8(1) January 2020 73”
BackgroundInfluentialKeller, J. K., Schwartz, T. L., Lizalek, J., Chang, E., Patel, A. D., Hurley, M. Y., & Hsueh, E. C. (2019) · Cancer Medicine · doi:10.1002/cam4.2128 · Cited by 75
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 89
Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
Poon, C. C., Gordon, P. M. K., Liu, K., Yang, R., Sarkar, S., Mirzaei, R., Ahmad, S. T., Hughes, M. L., Yong, V. W., & Kelly, J. J. (2019) · Oncotarget · doi:10.18632/oncotarget.26863 · Cited by 75
Garbe, C., Keim, U., Suciu, S., Amaral, T. M. S., Eigentler, T., Gesierich, A., Hauschild, A., Heinzerling, L., Kiecker, F., Schadendorf, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03034 · Cited by 82
“Both therapies were approved for adjuvant treatment in the United States, Europe, and many other countries.(28,29) The estimated hazard ratios for distant-metastasis–free survival were generally in the same range as for relapse-free survival.”
BackgroundSelf-citationEgger, M. E., Scoggins, C. R., & McMasters, K. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07828-4 · Cited by 73
Maurichi, A., Miceli, R., Eriksson, H., Newton‐Bishop, J., Nsengimana, J., Chan, M., Hayes, A. J., Heelan, K., Adams, D. J., Patuzzo, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01902 · Cited by 74
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 76
Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review
Gong, Z., & Wang, Y. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00002 · Cited by 75
Dousset, L., Poizeau, F., Robert, C., Mansard, S., Mortier, L., Caumont, C., Routier, É., Dupuy, A., Rouanet, J., Battistella, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00084 · Cited by 83
“PD-1 inhibitors (pembrolizumab and nivolumab) have been approved by the US Food and Drug Administration for metastatic melanoma, and recently in the adjuvant setting in stage III melanoma.(3,4) Although response rates (RR) are durable and remarkable, only approximately 35%-45% of patients benefit from these costly dru…”
BackgroundSelf-citationHamada, N., Maeda, A., Takase‐Minegishi, K., Kirino, Y., Sugiyama, Y., Namkoong, H., Horita, N., Yoshimi, R., Nakajima, H., & YCU irAE Working Group (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803410 · Cited by 80
“Ferris (14) 2016 HNSCC Recurrent After platinum-based chemotherapy Nivolumab MTX, Docetaxel, or Cetuximab 236 0 111 1”
BackgroundInfluentialDimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.004 · Cited by 75
Self-citationBatf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, J., Rozeman, E. A., O’Donnell, J. S., Allen, S., Fanchi, L., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1546068 · Cited by 70
Self-citationPaulson, K. G., Lahman, M. C., Chapuis, A. G., & Brownell, I. (2019) · International Immunology · doi:10.1093/intimm/dxz012 · Cited by 75
Kang, J., Jeong, J. H., Hwang, H.-S., Lee, S. S., Park, D. H., Oh, D., Song, T. J., Kim, K., Hwang, S., Hwang, D. W., et al. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.493 · Cited by 70
Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Herrscher, H., & Robert, C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000610 · Cited by 79
Self-citationPotential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Hsieh, C.-H., Jian, C.-Z., Lin, L., Low, G.-S., Ou, P.-Y., Hsu, C., & Ou, D. (2022) · Cancers · doi:10.3390/cancers14020294 · Cited by 73
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
Lucci, A., Hall, C. S., Patel, S. P., Narendran, B., Bauldry, J. B. B., Royal, R. E., Karhade, M., Upshaw, J. R., Wargo, J. A., Glitza, I. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2670 · Cited by 70
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69
Rawson, R. V., Adhikari, C., Bierman, C., Lo, S., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.006 · Cited by 72
Self-citationUnveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw, R. P. M., Thompson, J. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004884 · Cited by 73
Self-citationXue, C., Zhou, Q., Xi, H., & Zhou, J. (2022) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2022.10.008 · Cited by 72
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Durbin, S., Zubiri, L., Perlman, K., Wu, C., Lim, T., Grealish, K., Hathaway, N., LoPiccolo, J., Wang, M., Falade, A. S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2668 · Cited by 78
Shevtsov, M. A., Pitkin, E., Ischenko, A. M., Stangl, S., Khachatryan, W. А., Galibin, O. V., Edmond, S., Lobinger, D., & Multhoff, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00454 · Cited by 70
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
Patrinely, J. R., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1875639 · Cited by 64
“We observed a higher rate of severe (21%) extrahepatic toxicities than previously described.(20,21) While combination therapy with CTLA4 inhibitors has been known to increase the risk of severe irAEs, we found that combination therapy did not predict hepatitis severity, the need for second-line immunosuppressants, or…”
ResultSelf-citationProgress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor
Xiao, W., Song, M., Jiang, G., Liang, M., Chen, C., Yang, Z., & Zou, L. (2022) · Theranostics · doi:10.7150/thno.73566 · Cited by 68
“In the past decade, the clinical application of immune checkpoint inhibitors (ICIs) has greatly promoted the development of cancer immunotherapy [29-31].”
BackgroundTarhini, A., Lin, Y., Lin, H., Rahman, Z., Vallabhaneni, P., Mendiratta, P., Pingpank, J. F., Holtzman, M. P., Yusko, E. C., Rytlewski, J. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0428-5 · Cited by 63
Stein, C., Burtey, S., Mancini, J., Pelletier, M., Sallée, M., Brunet, P., Berbis, P., Grob, J., Honoré, S., Gaudy‐Marqueste, C., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa137 · Cited by 69
Self-citationCancer of Unknown Primary: Challenges and Progress in Clinical Management
Laprovitera, N., Riefolo, M., Ambrosini, E., Klec, C., Pichler, M., & Ferracin, M. (2021) · Cancers · doi:10.3390/cancers13030451 · Cited by 78
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
Clinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R. J., Silk, A. W., Zhou, A. Y., Compton, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1524695 · Cited by 69
Ignatiadis, M., Bailey, A., McArthur, H. L., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S. Y., Dieterich, M., Perretti, T., Shearer-Kang, E., et al. (2025) · JAMA · doi:10.1001/jama.2024.26886 · Cited by 78
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Bhave, P., Pallan, L., Long, G. V., Menzies, A. M., Atkinson, V. G., Cohen, J. V., Sullivan, R. J., Chiarion‐Sileni, V., Nyakas, M., Kähler, K. C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01121-y · Cited by 86
Self-citationBroman, K. K., Hughes, T. M., Dossett, L. A., Sun, J. X., Kirichenko, D., Carr, M. J., Sharma, A. S., Bartlett, E. K., Nijhuis, A. A. G., Thompson, J. F., et al. (2021) · Cancer · doi:10.1002/cncr.33483 · Cited by 64
“Presence of microsatellites 75 (9) 25 (13) .”
Deacon, D. C., Smith, E. A., & Judson‐Torres, R. L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642380 · Cited by 70
“Examples of adjuvant therapy include the combination of dabrafenib plus trametinib in resected Stage III BRAFV600E/K mutant melanoma, which improves 5 year overall survival (91), and pembrolizumab which improves relapse free survival in high risk, resected, Stage III melanoma patients (92).”
BackgroundDrug-induced sarcoidosis-like reactions
Miedema, J., & Nunès, H. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000800 · Cited by 64
Gorbet, M.-J., & Ranjan, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107456 · Cited by 68
Tiffen, J. C., Gallagher, S. J., Filipp, F. V., Gunatilake, D., Emran, A. A., Cullinane, C. M., Dutton‐Regester, K., Aoude, L. G., Hayward, N. K., Chatterjee, A., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.042 · Cited by 75
“Despite recent advances using immunotherapy and targeted therapies, not all patients respond to such treatments, and therapy resistance occurs in most initially responding patients (Eggermont et al., 2018; Long et al., 2018; Wolchok et al., 2017).”
BackgroundAmato, C. M., Hintzsche, J. D., Wells, K. R., Applegate, A. J., Gorden, N. T., Vorwald, V. M., Tobin, R. P., Nassar, K. W., Shellman, Y. G., Kim, J., et al. (2020) · Cancers · doi:10.3390/cancers12071943 · Cited by 66
Farooq, M. Z., Aqeel, S. B., Lingamaneni, P., Pichardo, R., Jawed, A., Khalid, S., Banskota, S. U., Fu, P., & Mangla, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7722 · Cited by 69
Amaral, T. M. S., Hoffmann, M., Sinnberg, T. W., Niessner, H., Sülberg, H., Eigentler, T., & Garbe, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.027 · Cited by 64
Zhu, X., Li, K., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.02.002 · Cited by 68
“For example, in a trial for pembrolizumab for advanced stage melanoma, where active control was used as a control, the sample size for each arm was 278(49); in the adjuvant settings, a placebo was used as a control, and the sample size for each arm was more than 500.(31) Also, in a clinical trial in which ipilimumab w…”
BackgroundMethodKanaki, T., Stang, A., Gutzmer, R., Zimmer, L., Chorti, E., Sucker, A., Ugurel, S., Hadaschik, E. N., Gräger, N., Satzger, I., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.011 · Cited by 62
Self-citationCurrent status of immunotherapy for advanced gastric cancer
Kawazoe, A., Shitara, K., Boku, N., Yoshikawa, T., & Terashima, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa202 · Cited by 67
Zhan, L., Feng, H.-F., Liu, H., Guo, L., Chen, C., Yao, X.-L., & Sun, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649863 · Cited by 65
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 66
Kroemer, G., & Zitvogel, L. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201979 · Cited by 62
Patrinely, J. R., Young, A. C., Quach, H., Williams, G. R., Ye, F., Fan, R., Horn, L., Beckermann, K. E., Gillaspie, E. A., Sosman, J. A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.05.005 · Cited by 61
“patients with stage III lung cancer treated with durvalumab after completion of chemoradiation) [3,4].”
BackgroundCurrent Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 80
Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma
Mason, R., Dearden, H. C., Nguyen, B., Soon, J. A., Smith, J. L., Randhawa, M., Mant, A. M., Warburton, L., Lo, S., Meniawy, T. M., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12831 · Cited by 60
Self-citationKennedy, O. J., Kiciński, M., Valpione, S., Gandini, S., Suciu, S., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.017 · Cited by 65
Self-citationYan, J., Liu, D., Wang, J., You, W., Yang, W., Yan, S., & He, W. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101037 · Cited by 65
Preferences for Immunotherapy in Melanoma: A Systematic Review
Livingstone, A., Agarwal, A. A., Stockler, M. R., Menzies, A. M., Howard, K., & Morton, R. L. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07963-y · Cited by 63
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
Bol, K. F., Schreibelt, G., Bloemendal, M., van Willigen, W. W., Bree, S. H.-D., de Goede, A. L., de Boer, A. J., Bos, K., Boer, T. D., Nordkamp, M. A. M. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45358-0 · Cited by 66
Self-citationPrinciples of Targeted Therapy for Melanoma
Sun, J. X., Carr, M. J., & Khushalani, N. I. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.013 · Cited by 63
Machiels, J., Tao, Y., Burtness, B. A., Tahara, M., Licitra, L. F., Rischin, D., Waldron, J. N., Simon, C., Grégoire, V., Harrington, K. J., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0184 · Cited by 59
Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandalà, M., Chiarion‐Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30940-9 · Cited by 58
Self-citationMoya‐Plana, A., Auperin, A., Obongo, R., Baglin, A., Ferrand, F. R., BAUJAT, B., Saroul, N., Casiraghi, O., Vergèz, S., Herman, P., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.007 · Cited by 58
Considering adjuvant therapy for stage II melanoma
Poklepovic, A. S., & Luke, J. J. (2019) · Cancer · doi:10.1002/cncr.32585 · Cited by 62
“Similarly, in the KEYNOTE-054 study (Study of Pembrolizumab [MK-3475] Versus Placebo After Complete Resection of High-Risk Stage III Melanoma, pembrolizumab demonstrated superiority to placebo in patients with completely resected stage III melanoma (stages IIIA, IIIB, and IIIC; AJCCv7).(21) Nivolumab and pembrolizumab…”
ResultAttrill, G. H., Owen, C. N., Ahmed, T., Vergara, I. A., Colebatch, A. J., Conway, J. W., Nahar, K. J., Thompson, J. F., da Silva, I. P., Carlino, M. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004771 · Cited by 64
Self-citationWright, F. C., Souter, L., Kellett, S., Easson, A. M., Murray, C., Toye, J., McCready, D. R., Nessim, C., Ghazarian, D., Hong, N. J. L., et al. (2019) · Current Oncology · doi:10.3747/co.26.4885 · Cited by 58
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 60
“(2018) [68] KEYNOTE-054 III Completely resected stage III disease A.”
BackgroundInfluentialAlbittar, A. A., Alhalabi, O., & Oliva, I. C. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_3 · Cited by 61
Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors
Gault, A., Anderson, A. E., Plummer, R., Stewart, C. J., Pratt, A. G., & Rajan, N. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19750 · Cited by 97
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
Ho, J., Mattei, J., Tetzlaff, M. T., Williams, M. D., Davies, M. A., Diab, A. K., Oliva, I. C. G., McQuade, J. L., Patel, S. P., Tawbi, H. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1001150 · Cited by 59
“KEYNOTE 054 excluded MM patients entirely (19).”
BackgroundWADA-OHNO, M., Ito, T., & Furue, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0666-x · Cited by 60
Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review
Bisschop, K., de Heer, E. C., Brouwers, A. H., Hospers, G. A. P., & Jalving, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103044 · Cited by 56
Mulder, E. E. A. P., Dwarkasing, J. T., Tempel, D., Spek, A., Bosman, L., Verver, D., Mooyaart, A. L., van der Veldt, A. A. M., Verhoef, C. K., Nijsten, T. E. C., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19499 · Cited by 56
Xu, T., & Gao, H. (2020) · Human Genomics · doi:10.1186/s40246-020-00265-5 · Cited by 68
“Even in the same pathology, the outcomes can vary significantly for lesions [67, 68].”
BackgroundTogo, M., Yokobori, T., Shimizu, K., Handa, T., Kaira, K., Sano, T., Tsukagoshi, M., Higuchi, T., Yokoo, S., Shirabe, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0820-z · Cited by 57
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Larroquette, M., Peyraud, F., Domblides, C., Lefort, F., Bernhard, J., Ravaud, A., & Gross‐Goupil, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102207 · Cited by 65
Metadata
- Authors
- Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C.
- Affiliations
- Aix-Marseille Université (FR)
- From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique–Hôpitaux de Marseille, Marseille (J.-J.G.) — all in France; Netherlands Cancer Institute–Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical...
- The University of Sydney (AU)
- The University of Queensland (AU)
- Edith Cowan University (AU)
- Washington University in St. Louis (US)
- University of Siena (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Eggermont, Alexander M.M.
- Blank, Christian U.
- Long, Georgina V.
- Atkinson, Victoria
- Dalle, Stéphane
- Haydon, Andrew
- Khattak, Adnan
- Carlino, Matteo S.
- Sandhu, Shahneen
- Larkin, James
- Puig, Susana
- Ascierto, Paolo A.
- Rutkowski, Piotr
- Schadendorf, Dirk
- Koornstra, Rutger
- Hernandez-Aya, Leonel
- Maio, Michele
- Grob, Jean-Jacques
- Gutzmer, Ralf
- Jamal, Rahima
- Lorigan, Paul
- Ibrahim, Nageatte
- Marreaud, Sandrine
- Suciu, Stefan
- Robert, Caroline
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1789-1801
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2797309423
- Cited by
- 1,906
- References
- 31
- Citations by year
- 2026: 131 · 2025: 171 · 2024: 207 · 2023: 204 · 2022: 236 · 2021: 308 · 2020: 307 · 2019: 250 · 2018: 87
- FWCI
- 88.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, adjuvant therapy, stage III melanoma, PD-1 inhibitors, PD-L1 expression, recurrence-free survival, resected melanoma, immune checkpoint inhibitors, adverse events, myositis, non-relapse mortality, overall survival, progression-free survival, high-risk melanoma, tumor recurrence prevention, safety and tolerability
- MeSH terms
- Adjuvants, Immunologic, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.